https://orcid.org/0009-0009-8859-6083
Figures & data
Table 1 Characteristics of Patients with First-Time Myocardial Infarction at the Time of Hospital Discharge, Denmark, 2010–2020
Table 2 Number and Incidence Rates of Cardiovascular Outcomes After Myocardial Infarction According to LDL-C Levels
Figure 1 Primary cardiovascular outcome associated with NSAID use vs non-use in myocardial infarction survivors, by baseline LDL-C levels. *Adjusted for age, sex, categorical DANCAMI score, inflammatory rheumatic disease, degenerative rheumatic disease, and concomitant medications. †A composite of recurrent myocardial infarction, ischemic stroke, and all-cause death. a6,953 patients with LDL-C <1.8 mmol/L and 43,620 patients with LDL-C ≥1.8 mmol/L. b2,944 patients with LDL-C <1.4 mmol/L and 47,629 patients with LDL-C ≥1.4 mmol/L.
Figure 2 Secondary cardiovascular outcomes associated with NSAID use vs non-use in myocardial infarction survivors, by baseline LDL-C levels. *Adjusted for age, sex, categorical DANCAMI score, inflammatory rheumatic disease, degenerative rheumatic disease, and concomitant medications. aAfter excluding patients with prior events of congestive heart failure: 45,752 patients in the total cohort, 22,840 with LDL-C <3.0 mmol/L, and 22,912 with LDL-C ≥3.0 mmol/L. bAfter excluding patients with prior events of atrial fibrillation of flutter: 46,994 patients in the total cohort, 23,168 with LDL-C <3.0 mmol/L, and 23,826 with LDL-C ≥3.0 mmol/L.
